ArticleMolecular diversity2026
CBInformax: bioactivity-aware self-supervised molecular representation learning for molecular property and drug-drug interaction prediction.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Molecular representation learning plays a central role in molecular property prediction and computer-aided drug discovery. Recent self-supervised pretraining methods have substantially improved molecular representations by exploiting large-scale unlabeled molecular data. However, most methods remain structure-centered and rely mainly on 2D or 3D molecular information, while overlooking bioactivity-related knowledge that can provide complementary functional signals. To address this limitation, we propose CBInformax, a bioactivity-aware self-supervised framework for molecular representation learning. CBInformax models each molecule from two complementary views: a 2D molecular graph and a bioactivity similarity network. A local encoder learns structure-based molecular representations from 2D graphs, whereas a global encoder captures inter-molecular relationships in the bioactivity space. The two views are aligned through a cross-view mutual-information maximization objective, enabling bioactivity-related knowledge to be transferred into structure-based embeddings during pretraining. Importantly, the pretrained molecular encoder can be directly fine-tuned for downstream tasks without requiring explicit bioactivity information at inference time. Experiments on multiple MoleculeNet benchmark datasets show that CBInformax achieves competitive or superior performance across classification and regression tasks. In addition, the learned representations improve drug-drug interaction prediction and exhibit enhanced sensitivity in distinguishing structurally similar molecules with subtle chemical differences. These results suggest that incorporating bioactivity similarity during pretraining can enrich molecular representations.
Indexed as
Identifiers
42545448What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.